Table 1.
Clinical Characteristics of Study Subjects
| Clinical characteristics OGTT status | NGT | IGT | DM | All | P‐value |
|---|---|---|---|---|---|
| N | 42 | 31 | 7 | 80 | – |
| Age (years) | 61.1 ± 17.2 | 66.3 ± 9.4 | 57.7 ± 15.1 | 62.8 ± 14.6 | 0.441 |
| Men/women | 15/27 | 13/18 | 5/2 | 33/47 | 0.209 |
| BMI (kg/m2) | 23.4 ± 3.9 | 24.6 ± 3.2 | 27.1 ± 4.4 | 24.2 ± 3.7 | 0.050 |
| Systolic blood pressure (mmHg) | 123.8 ± 14.1 | 129.7 ± 16.1 | 133.1 ± 10.7 | 126.9 ± 14.9 | 0.129 |
| Diastolic blood pressure (mmHg) | 73.8 ± 9.6 | 75.9 ± 11.5 | 82.6 ± 4.9 | 75.4 ± 10.3 | 0.092 |
| Hypertension (%) | 47.6 | 77.4 | 71.4 | 61.3 | 0.031* |
| Antihypertensive medication (%) | 38.1 | 51.6 | 71.4 | 46.3 | 0.199 |
| ACE inhibitors/ARBs (%) | 23.8 | 41.9 | 42.9 | 32.5 | 0.327 |
| Total cholesterol (mmol/l) | 5.05 ± 0.72 | 5.30 ± 1.21 | 4.99 ± 0.72 | 5.14 ± 0.94 | 0.784 |
| LDL cholesterol (mmol/l) | 2.86 ± 0.58 | 3.05 ± 0.91 | 2.99 ± 0.56 | 2.94 ± 0.72 | 0.733 |
| Triglycerides (mmol/l) | 1.20 ± 0.62 | 1.92 ± 3.06 | 1.54 ± 0.72 | 1.51 ± 1.99 | 0.294 |
| Serum albumin (g/l) | 44.0 ± 3.0 | 44.0 ± 2.0 | 45.0 ± 3.0 | 44.0 ± 3.0 | 0.930 |
| Uric acid (μmol/l) | 309.3 ± 89.2 | 303.3 ± 65.4 | 333.1 ± 35.7 | 309.3 ± 77.3 | 0.476 |
| FPG (mmol/l) | 5.03 ± 0.42 | 5.63 ± 0.60 | 6.35 ± 0.85 | 5.38 ± 0.67 | <0.001** |
| HbA1c (%) | 5.78 ± 0.33 | 6.16 ± 0.36 | 6.61 ± 0.47 | 6.00 ± 0.47 | <0.001** |
| Serum Cr (μmol/l) | 60.2 ± 10.6 | 59.3 ± 14.2 | 59.3 ± 10.6 | 59.3 ± 11.5 | 0.730 |
| Urinary pH | 6.19 ± 0.89 | 5.97 ± 0.71 | 6.00 ± 0.58 | 6.09 ± 0.80 | 0.491 |
Data are expressed as mean ± SD.
BMI, body mass index; LDL cholesterol, low‐density lipoprotein cholesterol; ACE inhibitors, angiotensin‐converting enzyme inhibitors; ARBs, angiotensin receptor blockers; FPG, fasting plasma glucose.
*P < 0.05; **P < 0.005.